These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
171 related articles for article (PubMed ID: 38470404)
1. Cost effectiveness of pembrolizumab plus lenvatinib compared with chemotherapy for treating previously treated advanced endometrial cancer in Sweden. Ralph L; Young K; Upadhyay N; Prabhu VS; Ljungcrantz C; Massaad R; Xu R; Giertz A; Merchant A; Orlowski R; Duska L J Med Econ; 2024; 27(1):483-491. PubMed ID: 38470404 [TBL] [Abstract][Full Text] [Related]
2. Cost-effectiveness of lenvatinib plus pembrolizumab versus chemotherapy for recurrent mismatch repair-proficient endometrial cancer after platinum-based therapy. Dioun S; Chen L; De Meritens AB; St Clair CM; Hou JY; Khoury-Collado F; Pua T; Hershman DL; Wright JD Gynecol Oncol; 2024 Mar; 182():70-74. PubMed ID: 38262241 [TBL] [Abstract][Full Text] [Related]
3. Cost-effectiveness of pembrolizumab compared with chemotherapy in the US for women with previously treated deficient mismatch repair or high microsatellite instability unresectable or metastatic endometrial cancer. Thurgar E; Gouldson M; Matthijsse S; Amonkar M; Marinello P; Upadhyay N; Nwankwo C; Aguiar-Ibáñez R J Med Econ; 2021; 24(1):675-688. PubMed ID: 33866938 [TBL] [Abstract][Full Text] [Related]
4. Pembrolizumab plus lenvatinib as first-line therapy for patients with mismatch repair-proficient advanced endometrial cancer: A United States-based cost-effectiveness analysis. Liu K; Zhu Y; Zhou Y; Zhang Y; Zhu H Gynecol Oncol; 2022 Sep; 166(3):582-588. PubMed ID: 35781166 [TBL] [Abstract][Full Text] [Related]
5. Phase 3, randomized, open-label study of pembrolizumab plus lenvatinib versus chemotherapy for first-line treatment of advanced or recurrent endometrial cancer: ENGOT-en9/LEAP-001. Marth C; Tarnawski R; Tyulyandina A; Pignata S; Gilbert L; Kaen D; Rubio MJ; Frentzas S; Beiner M; Magallanes-Maciel M; Farrelly L; Choi CH; Berger R; Lee C; Vulsteke C; Hasegawa K; Braicu EI; Wu X; McKenzie J; Lee JJ; Makker V Int J Gynecol Cancer; 2022 Jan; 32(1):93-100. PubMed ID: 34799418 [TBL] [Abstract][Full Text] [Related]
6. Analysis of East Asia subgroup in Study 309/KEYNOTE-775: lenvatinib plus pembrolizumab versus treatment of physician's choice chemotherapy in patients with previously treated advanced or recurrent endometrial cancer. Yonemori K; Fujiwara K; Hasegawa K; Yunokawa M; Ushijima K; Suzuki S; Shikama A; Minobe S; Usami T; Kim JW; Kim BG; Wang PH; Chang TC; Yamamoto K; Han S; McKenzie J; Orlowski RJ; Miura T; Makker V; Man Kim Y J Gynecol Oncol; 2024 Mar; 35(2):e40. PubMed ID: 38302725 [TBL] [Abstract][Full Text] [Related]
7. Lenvatinib Plus Pembrolizumab vs. Chemotherapy in Pretreated Patients With Advanced Endometrial Cancer: A Cost-Effectiveness Analysis. Feng M; Chen Y; Yang Y; Li Q Front Public Health; 2022; 10():881034. PubMed ID: 35619813 [TBL] [Abstract][Full Text] [Related]
9. Pembrolizumab and lenvatinib versus carboplatin and paclitaxel as first-line therapy for advanced or recurrent endometrial cancer: A Markov analysis. Ackroyd SA; Huang ES; Kurnit KC; Lee NK Gynecol Oncol; 2021 Aug; 162(2):249-255. PubMed ID: 34103196 [TBL] [Abstract][Full Text] [Related]
10. Lenvatinib plus pembrolizumab in the patients with advanced previously treated endometrial cancer: A cost-effectiveness analysis in the United States and in China. Liao X; Wu Y; Lin D; Gu D; Luo S; Huang X; Xu X; Weng X; Lin S J Obstet Gynaecol Res; 2024 May; 50(5):881-889. PubMed ID: 38485235 [TBL] [Abstract][Full Text] [Related]
11. Cost-effectiveness of Pembrolizumab as Second-line Therapy for the Treatment of Locally Advanced or Metastatic Urothelial Carcinoma in Sweden. Srivastava T; Prabhu VS; Li H; Xu R; Zarabi N; Zhong Y; Pellissier JM; Perini RF; de Wit R; Mamtani R Eur Urol Oncol; 2020 Oct; 3(5):663-670. PubMed ID: 31412001 [TBL] [Abstract][Full Text] [Related]
12. Lenvatinib plus pembrolizumab in advanced recurrent endometrial cancer: A cost-effectiveness analysis. Barrington DA; Haight PJ; Calhoun C; Tubbs C; Cohn DE; Bixel KL Gynecol Oncol; 2021 Sep; 162(3):626-630. PubMed ID: 34148720 [TBL] [Abstract][Full Text] [Related]
13. Lenvatinib plus pembrolizumab in Japanese patients with endometrial cancer: Results from Study 309/KEYNOTE-775. Yonemori K; Yunokawa M; Ushijima K; Sakata J; Shikama A; Minobe S; Usami T; Enomoto T; Takehara K; Hasegawa K; Yamagami W; Yamamoto K; Han S; Dutta L; Orlowski R; Miura T; Makker V; Fujiwara K Cancer Sci; 2022 Oct; 113(10):3489-3497. PubMed ID: 35612971 [TBL] [Abstract][Full Text] [Related]
14. Cost-effectiveness of Pembrolizumab for Patients with Advanced, Unresectable, or Metastatic Urothelial Cancer Ineligible for Cisplatin-based Therapy. Patterson K; Prabhu V; Xu R; Li H; Meng Y; Zarabi N; Zhong Y; Batteson R; Pellissier J; Keefe S; Grivas P; de Wit R Eur Urol Oncol; 2019 Sep; 2(5):565-571. PubMed ID: 31412011 [TBL] [Abstract][Full Text] [Related]
15. The cost effectiveness of pembrolizumab versus chemotherapy or atezolizumab as second-line therapy for advanced urothelial carcinoma in the United States. Slater RL; Lai Y; Zhong Y; Li H; Meng Y; Moreno BH; Godwin JL; Frenkl T; Sonpavde GP; Mamtani R J Med Econ; 2020 Sep; 23(9):967-977. PubMed ID: 32412387 [No Abstract] [Full Text] [Related]
16. Characterization and Management of Adverse Reactions in Patients with Advanced Endometrial Carcinoma Treated with Lenvatinib Plus Pembrolizumab. Makker V; Taylor MH; Oaknin A; Casado Herraez A; Orlowski R; Dutta L; Ren M; Zale M; O'Malley DM Oncologist; 2021 Sep; 26(9):e1599-e1608. PubMed ID: 34190370 [TBL] [Abstract][Full Text] [Related]
17. Cost-effectiveness analysis of pembrolizumab versus standard-of-care chemotherapy for first-line treatment of PD-L1 positive (>50%) metastatic squamous and non-squamous non-small cell lung cancer in France. Chouaid C; Bensimon L; Clay E; Millier A; Levy-Bachelot L; Huang M; Levy P Lung Cancer; 2019 Jan; 127():44-52. PubMed ID: 30642550 [TBL] [Abstract][Full Text] [Related]
18. Cost-effectiveness of pembrolizumab for the first-line treatment of patients with unresectable or metastatic MSI-H/dMMR colorectal cancer in the United States. Aguiar-Ibáñez R; Hardern C; van Hees F; Lee D; Patel A; Chhabra N; Baluni G; Amonkar M; Lai Y; Xu R; Massaad R; Fogelman D J Med Econ; 2022; 25(1):469-480. PubMed ID: 35184650 [TBL] [Abstract][Full Text] [Related]
19. Cost-effectiveness analysis of lenvatinib plus pembrolizumab compared with chemotherapy for patients with previously treated mismatch repair proficient advanced endometrial cancer in China. Zheng Z; Yang L; Xu S; Zhu H; Cai H Front Pharmacol; 2022; 13():944931. PubMed ID: 36249813 [No Abstract] [Full Text] [Related]
20. Lenvatinib plus Pembrolizumab Combination Therapy for Advanced or Recurrent Endometrial Cancer: A Single-Center, Retrospective Analysis. Tochigi M; Shigeta S; Shimada M; Miyahara S; Hasegawa-Minato J; Shibuya Y; Ishibashi M; Hashimoto C; Tokunaga H; Yaegashi N Tohoku J Exp Med; 2024 Feb; 262(2):85-95. PubMed ID: 38008437 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]